Psychedelics

Psychedelics are being fast-tracked for research after a 2026 executive order

Many such compounds (including LSD, psilocybin, and more) are classified as Schedule I drugs—illegal to possess and federally regarded as having no medical use. Researchers say such restrictions have created significant hurdles for formal clinical trials. With this executive order, the FDA will enable work particularly focused on depression, PTSD, and alcohol use disorder.

The FDA rejected MDMA-assisted therapy for PTSD in 2024, calling for more research

The decision was considered to be a major setback for moving psychedelics into the mainstream for mental health treatment. Pharmaceutical company Lykos, who had applied for the approval, had already attracted significant support from patients, politicians on both sides of the aisle, and leaders in the mental health field.

This is the human brain on the world's strongest psychedelic

Within seconds of inhaling a high dose of vaporized synthetic 5-MeO-DMT—a lab-produced substance that otherwise is naturally derived from the glands of the Colorado River toad—it induced slow brain waves. Such waves are typically associated with unconsciousness due to a coma or anesthesia, perhaps explaining why users describe feeling like everything falls away. The compound is currently in clinical trials for treating depression.

Researchers recently took an unprecedented look at the neural effects of psychedelics

According to analysis published in 2026 that looked at more than 500 brain scans pooled from 267 people who took psychedelics, the drugs increase connectivity between different brain regions within minutes of taking them, including transmodal networks (tied to thinking) and unimodal networks (involved in visual and sensory perception).

Merck developed MDMA in the early 1900s as part of its effort to create a blood clotting drug

The company's chemists were attempting to synthesize a substance that could compete with an existing patent for the best clot medicine of that time, hydrastinine. MDMA was the byproduct of that effort.

Psychedelic DMT—part of ayahuasca—shows antidepressant promise in small clinical trial

Proponents say this short-acting psychedelic, formally known as dimethyltryptamine, could be particularly promising for medicinal use because longer-acting psychedelics can sideline someone for hours after a treatment with hallucinations. DMT is the primary psychoactive ingredient in ayahuasca, a psychoactive brew used across various South American cultures for spiritual, social, and medicinal purposes.

How a dose of MDMA transformed a white supremacist

A man leading a faction of the US white nationalist movement took part in a psychedelic trial on the pleasantness of social touch and came away from it with his beliefs reportedly upended. He left researchers a note on a form, stating, "this experience has helped me sort out a debilitating personal issue. Google my name. I now know what I need to do."

Psychedelics interact with neurotransmitter systems to alter one's perception

LSD, psilocybin, and MDMA can suppress the brain's default mode network and enhance connectivity. Research shows that, when paired with therapy, psychedelics may help treat mental health conditions, including depression, addiction, and PTSD.

Psychedelics set off a flurry of brain activity that may permanently alter it

The brain seems to experience a sharp increase in communication between areas that generally don't interact. New research suggests a thin, sheet-like gray matter structure tucked deep within the brain, between the insular cortex and striatum, may be the key to this change. The area is centrally located and home to many of the receptors that psychedelics target, potentially rewiring the brain and rewriting thought patterns.

Ibogaine, a psychedelic substance, can be used to treat mental illness

Although the substance is banned in the US, it's legal in Mexico. Americans who have traveled there for treatment, including the NFL's Braden Smith, say the drug helps deal with conditions like obsessive-compulsive disorder.